Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2010 /
Zoledronic acid disappointment for early breast cancer

8th - 12th Dec 2010

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.01.11
Views: 5290
Rating:

Prof Michael Gnant - Medical University of Vienna, Austria

Professor Michael Gnant talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium. Zometa, an osteoporosis drug from Novartis, failed to improve disease free survival of early breast cancer patients in a substantial clinical trial. The AZURE trial included 3360 patients from 174 centres. Prof Robert Coleman, of the University of Sheffield, England, and colleagues including Prof Gnant, randomized stage II and III patients to standard therapy or standard therapy plus zoledronic acid for five years. The use of Zometa made no difference to survival in the study's overall population though there was some benefit in older patients. There was a 29 percent improvement in overall survival observed in the 1,101 patients who were five years post-menopause. Prof Gnant also discusses his abstract on the carry-over effect of adjuvant zoledronic acid: “Comparison of 48- and 62-month analyses of ABCSG-12 suggests that the benefits of combining zoledronic acid with adjuvant endocrine therapy persist long after completion of therapy”.

Categories:

Breast · Drug development · SABCS 2010

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation